Drug Trial Radar · NCT07349615
A Study of SHR-1918 In Participants With Hypertriglyceridemia
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
367
Actual
Start
Mar 31, 2026
Primary completion
Mar 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Beijing Suncadia Pharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypertriglyceridemia. The efficacy and safety of SHR-1918 will be evaluated after 24-weeks and 48-weeks treatment.
Conditions
- Hypertriglyceridemia
Interventions
SHR-1918/ SHR-1918 placeboDrug
SHR-1918/ SHR-1918 placebo Dose 1
SHR-1918/ SHR-1918 placeboDrug
SHR-1918/ SHR-1918 placebo Dose 2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in mean serum triglyceride (TG) levels at Week 20 and Week 24 relative to baselineTime frame: at 20 weeks and 24 weeks of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongshan Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.